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The existence of thresholds for toxicants is a matter of debate in chemical risk assessment and regulation. Current risk
assessment methods are based on the assumption that, in the absence of sufﬁcient data, carcinogenesis does not have a
threshold, while noncarcinogenic endpoints are assumed to be thresholded. Advances in our fundamental understanding of
theeventsthatunderlietoxicityareprovidingopportunitiestoaddresstheseassumptionsaboutthresholds.Akeyeventsdose-
response analytic framework was used to evaluate three aspects of toxicity. The ﬁrst section illustrates how a fundamental
understanding of the mode of action for the hepatic toxicity and the hepatocarcinogenicity of chloroform in rodents can
replace the assumption of low-dose linearity. The second section describes how advances in our understanding of the
molecular aspects of carcinogenesis allow us to consider the critical steps in genotoxic carcinogenesis in a key events
framework. The third section deals with the case of endocrine disrupters, where the most signiﬁcant question regarding
thresholds is the possible additivity to an endogenous background of hormonal activity. Each of the examples suggests that
current assumptions about thresholds can be reﬁned. Understanding inter-individual variability in the events involved in
toxicological effects may enable a true population threshold(s) to be identiﬁed.
Keywords low-dose dose-response, chloroform, endocrine disruptors, non-genotoxic carcinogen, genotoxic carcinogen,
thresholds
INTRODUCTION
The risk assessment of low molecular weight chemicals
(which include many human and veterinary drugs, environ-
mental contaminants, pesticides, industrial chemicals, food
additives, and ﬂavorings, etc.) depends considerably upon
conclusions about the nature of the dose-response relationship
for the critical toxicological effect. Speciﬁcally, the approach to
chemicals for which there is no evidence of a threshold in their
dose-response curve is different from that of chemicals where
a threshold is observed or assumed. In the former situations,
the approach also varies with jurisdiction. For example, in
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the United States, depending on the intended use of the
chemical, linear extrapolation from a point of departure on the
dose-response curve to a virtually safe dose may be undertaken
(Fig. 1). In Europe, for substances whose exposure is avoidable,
the ALARA (as-low-as-reasonably-achievable) principle may
be invoked. Recently, for those substances where exposure may
be difﬁcult or impossible to avoid, a margin of exposure (MOE)
between a point of departure and estimated human exposure is
calculated to help provide advice on the relative magnitude of
the risk and the priority for risk management action (Barlow
et al., 2006).
Where compounds are thought to exhibit a threshold in their
dose-response curve, a deterministic approach is often adopted
in assessing acceptability of exposure (Boobis, 2007). A point
of departure on the dose-response curve is divided by an un-
certainty (or safety or adjustment) factor, to allow for inter-
species and inter-individual differences, thereby identifying the
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Figure 1 Extrapolation to human exposure when the dose-response curve
cannot be assumed to exhibit a threshold. The data in the observable range
(typically a response of 10–100% in a cancer bioassay) are used to determine
a point of departure (POD) (e.g. NOAEL, BMDL10). The POD is used to
extrapolate linearly to a virtually safe dose, that is usually associated with a risk
of 1 in 105 or 1 in 106, the choice of value being a risk management decision.
Note that the axes are plotted on logarithmic scales, because of the range over
which extrapolation is necessary.
equivalent point of departure on the dose-response curve for a
sensitive individual (Fig. 2). In the absence of speciﬁc informa-
tion, a default value is used for the uncertainty factor, while if
speciﬁc information is available on either inter-species or inter-
individual differences in toxicokinetics or toxicodynamics, this
can be used to derive a chemical speciﬁc adjustment factor, as
described by IPCS (Meek et al., 2002).
There is therefore considerable interest in improving meth-
ods for establishing whether a toxicological response exhibits
Figure 2 Extrapolation to human exposure when the dose response-curve
can be assumed to exhibit a threshold. The data in the observable range are used
to determine a point of departure (POD) (e.g. NOAEL, BMDL10). The POD
is used to determine the equivalent dose in a sensitive human by dividing it
by an uncertainty factor, to allow for possible inter-species and inter-individual
differences. The default values are normally 10-fold. The inter-species factor
is used to determine the POD in an average human (leftward shifted sigmoidal
curve). Within the population there will be a range of sensitivities, reﬂected by a
distributionofPODs(Gaussiancurve).Thefactorforinter-individualsensitivity
is used to determine the POD in a sensitive subject, which will lie towards the
far left of the distribution curve. This POD has been termed a reference value
(RV), for example the tolerable daily intake (TDI).
a threshold and in developing procedures for identifying such
thresholds. These thresholds in the dose-response curve for a
toxicologicalresponseinagenetically(relatively)homogeneous
species have been termed biological thresholds.1 In contrast,
within the human population each individual will exhibit a dif-
ferent sensitivity, giving rise to the concept of a population
threshold, a dose below which no one is sensitive (see Fig. 2).
The sensitivity of all experimental studies in laboratory
species or humans and observational (epidemiological) studies
in humans is limited by factors such as the number of observa-
tional units (e.g. volunteers), the frequency of the response, and
thesensitivity(orreliability)ofthedetectionmethods. Hence, it
is not possible to prove the existence of a threshold by empirical
observation (although it may be possible to prove nonlinearity
of the dose-response curve). Currently, conclusions on whether
a speciﬁc toxicological response exhibits a threshold are based
on a combination of observation, biological plausibility, and ac-
cumulated experience. However, the view has been expressed
recently that the risk assessment of effects previously based on
a threshold approach should move to linear low-dose extrapola-
tion (e.g. White et al., 2009). The development of a systematic
approachtoexplorewhetheragiventoxicologicalresponsedoes
exhibit a biological threshold using a key events dose-response
frameworkbasedonthemodeofactionrespondstothisconcern.
The International Life Sciences Institute Research Founda-
tion (ILSI RF) convened an international group of experts with
tripartitecomposition,drawnfromindustry,academia, andgov-
ernment agencies, to address this question (see Julien et al.,
2009, in this issue). The group addressed a number of classes
of substance—nutrients, allergens, microbial agents, and chem-
icals. As part of the exercise, case studies were developed to
examinetheutilityoftheapproachproposedandtoidentifydata
gaps and research needs. This manuscript describes case studies
applying the framework described below to chemicals, includ-
ing chloroform as a member of the group of nonDNA-reactive,
nonmutagenic carcinogens, DNA-reactive carcinogens, and
endocrine-disrupting chemicals as a representative class of
noncarcinogens.
THE KEY EVENTS DOSE-RESPONSE FRAMEWORK
As discussed above, due to limitations that all studies have, it
isnotpossibletoprovetheexistenceofabiologicalthresholdby
observation alone. Hence, a mechanistic approach is required.
The approach adopted was based on the concept of the mode of
action(MOA),reﬁnedforchemicalriskassessmentoverthepast
decade or so, particularly with the development by the WHO
International Programme on Chemical Safety (IPCS) and ILSI
(Sonich-Mullin et al., 2001; Meek et al., 2003; Boobis et al.,
2006, 2008) of an analytic framework based on systematic eval-
uation of key events. A mode of action for a toxicological effect
is a biologically plausible sequence of key events, starting with
1Wheretheterm“threshold”isusedonitsowninthisdocument,itreferstoabiological
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Figure 3 A generic representation of a mode of action for a toxicological effect as a series of key events. Note that often the early (upper) key events will
be primarily toxicokinetic while the later (lower) ones will be largely toxicodynamic. Each key event is necessary but not sufﬁcient to produce the toxicological
effect. Each key event will exhibit its own dose-response curve, and possibly a threshold. The presence of a threshold, determined by the factors illustrated to the
right hand side of the ﬁgure, will dictate whether there is progression to the next key event at a given dose. The toxicological effect will be manifest only if all key
events operate.
the interaction of an agent with a cell, through functional and
anatomical changes, leading to an observed effect supported by
robust experimental observations and mechanistic data. A key
eventisdeﬁnedasanempiricallyobservable,precursorstepthat
is a necessary element of the mode of action, or is a marker for
suchanelement(Fig.3).Therelevanceofakeyeventinapartic-
ularmodeofaction,andofthemodeofactionoverall,areevalu-
ated using a weight of evidence approach based on the Bradford
Hill criteria (Sonich-Mullin et al., 2001). The hypothesis is that
by identifying the key events for a speciﬁc toxicological effect,
these would be more amenable to the experimental demonstra-
tion of a threshold than the effect itself. It would be possible
to utilize information on speciﬁc interventions, biological and
chemical analogy, and the genetic differences in exploring the
evidence for thresholds in a key event. Key events are, in prin-
ciple, quantiﬁable by deﬁnition. An analysis of dose-response
concordance should enable the identiﬁcation of a rate limiting
key event for the MOA and whether any one key event is the
critical determinant of the response.
The importance of this approach is reﬂected in the views of a
number of regulatory agencies. For example, in the current US
EPA Guidelines for Cancer Risk Assessment (US EPA, 2005),
the following points are emphasized:
“Whenadequatedataonmodeofactionprovidesufﬁcientev-
idencetosupportanonlinearmodeofactionforthegeneralpop-
ulation and/or any subpopulations of concern ...—a reference
dose/reference concentration that assumes that nonlinearity—
is used.”
“A sufﬁcient basis to support this nonlinear procedure is
likely to include data on responses that are key events integral
to the carcinogenic process.”
“This means that the POD may be based on these precursor
response data, for example, hormone levels or mitogenic effects
rather than tumor incidence data.”
This provides a real incentive to develop a robust approach
for establishing nonlinearity of the dose-response curve using
a mode of action, key events dose-response framework. Risk
assessment based on demonstrable thresholds would increase
the conﬁdence of both risk managers and consumers. It would
ensure the protection of public health, while not jeopardizing
socio-economic development.
CASE STUDY: CHLOROFORM
Among the case studies considered by the ILSI RF work-
ing group, examples of target organ toxicity and cancer by a
nongenotoxic mechanism were sought. Chloroform was con-
sidered a useful example, as it is both toxic to target organs and
carcinogenic by a nongenotoxic mode of action. The evidence
that chloroform causes cancer by a nongenotoxic mode of ac-
tion has been reviewed on a number of occasions. In his review,
Komulainen (2004) stated that “The mainly negative and incon-
sistent genotoxicity data suggest that neither chloroform nor its
metabolites react directly with DNA to cause DNA damage.”
Similarly, in a comprehensive evaluation of the toxicity and car-
cinogenicity of chloroform published in 2004, IPCS concluded
that “most studies did not identify genotoxic potential for chlo-
roform. Results from a few, nonstandard studies indicate the
possibility of a weak positive response in rats. Overall, how-
ever, the weight of evidence indicates that chloroform does not
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Hence, chloroform can serve as a case study for both the
toxicity to target organs and carcinogenicity by a nongenotoxic
mode of action. In addition, it is a well-studied chemical, with
a wealth of information available in the public domain. Chlo-
roform is nephrotoxic, nephrocarcinogenic, hepatotoxic, and
hepatocarcinogenic, depending on the species, the strain, and
sex. There is evidence that all of these effects share key events
and hence, will be considered together.
Hypothesized Mode of Action
Chloroform is metabolized by CYP2E1 to a cytotoxic prod-
uct (phosgene), which can bind covalently to tissue macro-
molecules,includingproteins,andcangeneratereactiveoxygen
species. In those tissues with high CYP2E1 levels, the local for-
mation of cytotoxic products leads to sustained cell death, with
resultantorgantoxicity.Persistentnecrosisleadstoregenerative
hyperplasia which eventually results in the formation of tumors
(Fig. 4). There are marked species, strain, and sex differences in
susceptibility, both to organ toxicity and to carcinogenicity. The
weight of evidence supporting this mode of action for chloro-
form has been reviewed in detail elsewhere (Meek et al., 2003).
Key Events for Organ Toxicity and Tumor Development
1. Absorption and distribution of chloroform to target tissue
2. Generation of cytotoxic metabolite (phosgene) by P450
(CYP2E1)
3. Sustained cytotoxicity
4. Regeneration and proliferation
Each key event is considered with respect to what is known
about the dose-response characteristics of the event, including
whether the event may be thresholded. The roles of protec-
tive response mechanisms (e.g., detoxiﬁcation, repair, adaptive
mechanisms) are discussed, together with factors that may con-
tribute to variability in the effectiveness of these mechanisms
(e.g., environmental, genetic, etc.).
Key Event 1—Absorption and Distribution to Target Tissue
Chloroform is a low molecular weight (MR 119.4), lipid sol-
uble (log P 1.97) compound that is a liquid at normal tem-
perature and pressure. As such, it is readily absorbed from
most sites of exposure, particularly the gastrointestinal tract
and the lungs. However, the absorption rate is affected by the
method of delivery, for example whether by oral gavage in
corn oil or in drinking water. Distribution is rapid and exten-
sive, with exposure of all tissues. Hence, target organ speci-
ﬁcity is determined more by local metabolism than by systemic
pharmacokinetics.
As chloroform is lipid soluble, its distribution into fat can
inﬂuence systemic levels. Similarly, the rate of systemic re-
moval can inﬂuence systemic levels. There is evidence that the
elimination of chloroform at higher doses is saturable, so that
systemic, and hence target tissue, exposure increases dispro-
portionately at high doses (Anand et al., 2003; 2006). This is
particularly notable after a single exposure. It is very unlikely
that accumulation in fat per se is saturable, even at doses used
experimentally. Repeated exposure results in increased elimina-
tion of chloroform, at least in mice, by mechanisms that have
yet to be determined (Anand et al., 2006).
Figure 4 Postulated mode of action and key events for the hepatic toxicity and hepatocarcinogenicity of chloroform. Some of the factors that can inﬂuence
the dose-response relationships of the key events, and whether they are likely to exhibit a threshold, are illustrated. The early (upper) key events are largely
toxicokinetic while the later (lower) key events are largely toxicodynamic.694 A. R. BOOBIS ET AL.
As a consequence of these phenomena, the AUC for chloro-
form in blood following a single oral aqueous gavage dose to
miceincreased6-foldfordosesof150mg/kgbwand300mg/kg
bw, respectively. Target organ AUC increased to a similar ex-
tent, 8-fold in both liver and kidney. Cmax for chloroform also
showed nonlinear increases with dose, 7-fold in blood, 8-fold
in liver, and 9-fold in kidney. Following repeated exposure for
30 days, the target organ AUC increased only 3–4-fold over this
doserange,whileCmaxincreasedlessthan2-fold(Anandetal.,
2006). As a consequence of these changes, while the target or-
gan Cmax showed very little variation with repeated exposure
at a dose of 150 mg/kg bw, at high doses of 300 mg/kg the target
organ Cmax varied 8-fold in liver and 18-fold in kidney be-
tween one and 30 days exposure. AUC showed similar, though
less marked differences, 4–6 fold at the low dose, and 9–13 fold
at the high dose.
Fold increase in AUC and Cmax after single
dose (300 mg/kg bw compared with 150 mg/kg bw)
AUCb AUCorg Cmaxb Cmaxorg
6X 8X 7X 8-9X
Fold increase in AUC and Cmax on day 30
after repeated daily dose (150 mg/kg bw)
AUCb AUCorg Cmaxb Cmaxorg
0.3X 0.2-0.25X 1X ∼ 1X
Fold increase in AUC and Cmax on day 30
after repeated daily dose (300 mg/kg bw)
AUCb AUCorg Cmaxb Cmaxorg
0.25X 0.08-0.11X ∼ 0.2X 0.13X liver
0.06X kidney
As noted above, exposure at high doses is inﬂuenced by
saturation of elimination. However, repeated exposure at low
doses appears to engage physiological response mechanisms
that lead to increased elimination, reduction of AUC and Cmax,
and decreased target tissue dose—i.e., changes that would be
expected to affect the magnitude of the biological response,
and there is evidence that this is so with tolerance to the target
organ toxicity of chloroform developing on repeated exposures
(Anand et al., 2006). The effects may be of such a magnitude as
to reduce target organ exposure to below that level necessary to
provoke any biological response at all.
In summary, target tissue dose levels of chloroform are af-
fectednotonlybyadministereddose,butbyhostresponsemech-
anisms that have not yet been elucidated. These host response
mechanisms may include adaptive or protective response mech-
anismsthatservetoincreaseeliminationandtherebyreducetar-
gettissuedosewithrepeatedexposure.Animportantunknownis
the relationship between the dose level and frequency of dosing
at which such adaptive response mechanisms are engaged, and
indeed whether this is consistent across species. At high dose,
eliminationissaturable;however,atrepeatedlowdose,elimina-
tion may be up-regulated. It is not known at what combination
of dose level and frequency saturation of elimination begins to
occur. Nor is information yet available on what conditions of
doselevelandfrequencyarerequiredforup-regulationtooccur.
Key Event 2—Generation of a Cytotoxic Metabolite
(Phosgene) by P450 (CYP2E1)
Chloroform itself is relatively unreactive but on P450-
mediated oxidative metabolism, it forms one or more chem-
ically unstable products that are cytotoxic (Pohl et al., 1977;
Pohl and Krishna, 1978; Smith and Hook, 1984). Most, if not
all,ofthemetabolismofchloroformiscatalyzedbytheethanol-
inducible form of P450, CYP2E1. This enzyme exhibits classic
Michaelis-Menten kinetics (Lipscomb et al., 2004), i.e.
ν =
Vmax × S
Km + S
where ν is the velocity of the enzyme reaction, Vmax is the
maximum velocity of the reaction, Km is the Michaelis-Menten
constant (a measure of afﬁnity), and S is the substrate concen-
tration. Hence, at low levels of exposure the rate of metabolism
will be essentially linear with dose, and no threshold will exist
(Fig. 5). At high doses, saturation will occur.
Chloroform is cytotoxic only in tissues in which CYP2E1
is expressed; moreover, the extent of tissue necrosis and the
speciﬁc regions of tissue necrosis correlate with the extent of
Figure 5 Substrate concentration-reaction velocity curve for an enzyme re-
action exhibiting Michaelis-Menten kinetics. The enzyme saturates at high con-
centrations, reaching a maximum velocity (Vmax). The concentration at which
the enzyme velocity is 50% of its maximum is a measure of the enzyme afﬁn-
ity, Km. At low substrate concentrations (up to 50% saturation), the reaction is
essentially linear with substrate concentration.APPLICATION OF KEY EVENTS ANALYSIS TO CHEMICAL CARCINOGENS AND NONCARCINOGENS 695
Figure 6 Metabolic activation of chloroform to phosgene and subsequent detoxication by glutathione. Chloroform is oxidized by CYP2E1 to an unstable
hydroxylated intermediate, which spontaneously rearranges to the chemically reactive phosgene, the putative toxic species. Phosgene can react spontaneously with
glutathione (GSH), the product of which is non-toxic. The glutathione conjugate is further metabolised via γ-glutamyltranspeptidase and cysteinylglycinase to
yield 2-oxo-thiazolidine-4-carboxylic acid (OTZ), an unreactive product.
metabolic activation (as measured by covalent binding to pro-
tein). When CYP2E1 is inhibited chemically and in CYP2E1
knockout mice, null only for this form of P450, there is no toxi-
city to liver or kidney of mice in which chloroform is otherwise
toxic (Constan et al., 1999). Thus, the level of CYP2E1 expres-
sion is clearly a critical determining factor in whether, and the
extent to which, chloroform is toxic to target tissues.
Quantitatively, the most important reactive metabolite of
chloroformisphosgene(Pohletal.,1984;Ammannetal.,1998;
Gemma et al., 2004). Phosgene is highly reactive and does not
diffuse far from its site of formation before reacting with thiols,
including the cellular nucleophile glutathione, which detoxiﬁes
phosgene, forming diglutathionyl dithiocarbonate (Fig. 6) (Pohl
et al., 1981). Glutathione may have a dual role in preventing the
cytotoxicity of chloroform, through detoxiﬁcation of phosgene
and through the reduction of oxidized groups in critical macro-
molecular targets (Burke et al., 2007). As a consequence of the
reactivity of phosgene, the sites of toxicity for chloroform are
determined by local metabolism to reactive products.
At low rates of chloroform metabolism, endogenous levels
of glutathione will attenuate, if not prevent, the toxicological
response. There is evidence, however, that exposure to chloro-
form at a sufﬁciently high dose results in a depletion of target
organ glutathione levels (Wang et al., 1997, Burke et al., 2007),
but a threshold level of chloroform metabolism is necessary
for such depletion to occur (Ammann et al., 1998). Depletion
of glutathione would be expected to increase available levels
of reactive metabolite. (Stevens and Anders, 1981, Beddowes
et al., 2003), and in fact, when glutathione is depleted prior to
the administration of chloroform, dose levels producing no ob-
servable toxicity in liver or kidney were toxic to both tissues in
mice (Kluwe and Hook, 1981).
Tissue levels of CYP2E1 show appreciable interindividual
variability (Fig. 7); for example, the speciﬁc hepatic content of
CYP2E1 in adults varies by 10–12 fold (Edwards et al., 1998;
Lipscomb et al., 2004).2 A variety of environmental and patho-
physiological factors inﬂuence hepatic expression. CYP2E1 is
inducible by low molecular weight solvents such as acetone
and ethanol, by isoniazid therapy for tuberculosis, by certain
physiological states such as fasting, and in some disease condi-
tions such as diabetes (reviewed in Cederbaum, 2006). There is
also indirect evidence for induction of liver CYP2E1 content in
humans after drinking ethanol-containing beverages (Tsutsumi
et al., 1989), or after treatment with isonizaid for some time.
Paradoxically, CYP2E1 is inhibited by many of the compounds
that can act as inducers, when exposure is acute, including
ethanol, other solvents, and a variety of halogenated hydro-
carbons (Ronis et al., 1996; Ohashi et al., 2005). A number of
dietary constituents, such as diallyl sulphide, may also inhibit
CYP2E1toagreaterorlesserextent(LoizouandCocker,2001).
2While low levels of CYP2E1 can be detected in rodent kidney (Wilke et al., 1994;
Poloyac et al., 2004), CYP2E1 was not detectable in samples of human kidney (Amet et al.,
1997; Baker et al., 2005)696 A. R. BOOBIS ET AL.
Figure 7 Interindividual variability in human hepatic CYP2E1 content. The
illustration is of Western blots of equal protein loading from 30 microsomal
samples of human liver, each from a different renal transplant donor, with a
highly speciﬁc anti-CYP2E1 antibody. Donors had no evidence of liver pathol-
ogyeitherhistologicallyorbyclinicalchemistry.“P”representsapooledsample
used for quality control. (Edwards et al.,1998).
Certain genetic factors may also contribute to interindividual
variability. CYP2E1 is genetically polymorphic (Hayashi et al.,
1991; Hu et al., 1997) and some of the variants have been re-
portedtoaffectCYP2E1activity.However,theevidenceregard-
ing the impact of such polymorphism is somewhat inconsistent
and any effect appears relatively modest (Ingelman-Sundberg,
2004).
Given the importance of CYP2E1 activity in the etiology of
chloroform toxicity, variability in CYP2E1 levels may be a ma-
jorcontributingfactortointer-andintra-individualvariabilityin
response to chloroform. In general, CYP2E1 expression is not
detectable during the ﬁrst two trimesters of pregnancy (Jones
et al., 1992, Johnsrud et al., 2003), but expression increases dur-
ing gestation and neonatal life, and reaches adult levels within
3 months of birth (Johnsrud et al., 2003).
Enzyme (CYP2E1)-catalyzed formation of phosgene from
chloroform obeys Michaelis-Menten kinetics, and hence there
willbenodosebelowwhichphosgeneisnotproduced.However,
levelsofphosgenecanbedetoxiﬁedbyglutathione,althoughthe
efﬁciency of this process is not clear. Nevertheless, as CYP2E1
expression increases and/or GSH levels decrease, the location
of the threshold for the effects of chloroform will decrease and
thedose-responsecurvewillbecomesteeper.Itislikelythatloss
of protection by GSH will not become apparent until there is
marked depletion of this nucleophile. Given the large size of the
GSH pool and its rapid rate of resynthesis, frequent high doses
of chloroform or some other similar agent would be necessary
to compromise GSH-mediated protection. In some individuals,
susceptibility may be increased by rare inborn errors of GSH
synthesis or by pathophysiological states which markedly affect
GSH levels, e.g. hepatic failure, although any contrary effects
on CYP2E1 activity would need to be taken into account.
The sources of variability in the expression level and activity
of CYP2E1 will affect the rate of formation of phosgene from
chloroform and hence, interindividual susceptibility to the ef-
fects of chloroform. The practical consequence of this would be
that for a given individual, the threshold for generation of a crit-
ical concentration of phosgene would vary with their CYP2E1
phenotype, as determined by both genetic and environmental
factors. It is anticipated that variations in CYP2E1 will be a
greater determinant of interindividual differences in suscepti-
bility to chloroform than variations in GSH concentration, for
the reasons outlined above.
Key Event 3—Sustained Cytotoxicity
The toxic product(s) of chloroform metabolism, predomi-
nantly, if not exclusively, phosgene (Pohl et al., 1977; Pohl
and Krishna, 1978; Pohl et al., 1984), is a highly reactive elec-
trophileandreadilyreactswithnucelophiles,suchasglutathione
and macromolecules, including proteins, producing covalent
adducts (Reynolds and Yee, 1967; Branchlower et al., 1984).
Modiﬁcation and/or oxidation of critical macromolecules lead
to cytotoxicity and necrosis (Constan et al., 1999). The extent
to which oxidative stress is involved in the toxicity of chloro-
formisunclear,theevidencebeinginconsistent(Ammannetal.,
1998; Burke et al., 2007).
The mechanism of cell death has yet to be clearly deter-
mined, but there are data suggesting that it involves mitochon-
drial dysregulation leading to impairment of the mitochondrial
membrane potential via effects on mitochondrial permeability
transition (Hartig et al., 2005; Burke et al., 2007).
There is evidence that cell death (cytotoxicity) occurs only
after a critical degree of damage to the cell and there is an ob-
servable threshold for cytotoxicity, both in vitro (Ruch et al.,
1986; Ammann et al., 1998; Smith et al., 1985) and in vivo
(Smith et al., 1983; Larson et al., 1994; Templin et al., 1998).
Belowcertainchloroformlevels,notoxicityisapparentineither
liver or kidney. Further support for a threshold comes from the
marked species, strain, sex, and tissue speciﬁcity of the toxicity
of chloroform to the liver and kidney. For example, gavage dos-
ingofOsborne-Mendelratswithchloroformtohighdoselevels,
causes renal toxicity only in males (Templin et al., 1996a). No
evidence for renal toxicity is found in females. Low levels of
damage are not sufﬁcient to cause cytotoxicity (Hartig et al.,
2005), as repair and/or resynthesis of damaged proteins enables
cellularrecovery(Fig.8).Atpresent,thereisempiricalevidence
for cellular repair of damage following exposure to chloroform
(Liaoetal.,2007),butspeciﬁcmechanisticinformationisnotyet
available. Such evidence is emerging for other toxicants caus-
ing damage to liver or kidney (Bang et al., 2008), but the extent
to which the same processes extend to chloroform remains to
be determined. In support of this, it has been shown that mito-
chondria can sustain a certain degree of insult before there is
anychangeinmembranepermeability,whichisthedetermining
factor in cytotoxicity (Zorov et al., 2006). These processes are
ubiquitous, and human cells show similar threshold behavior to
thosefromexperimentalanimals(Teeetal.,1987).Cytotoxicity
ofchloroformtotheliverandthekidneyrequirescontinuousex-
posure. When exposure stops, there is recovery from the tissue
damage sustained (Templin et al., 1996b).
Key Event 4—Regeneration and Proliferation
Unless necrosis is so extensive that no viable cells remain,
in many tissues the surviving cells will undergo compensatoryAPPLICATION OF KEY EVENTS ANALYSIS TO CHEMICAL CARCINOGENS AND NONCARCINOGENS 697
Figure 8 Reversibility of initial damage to hepatocytes. Freshly isolated hamster hepatocytes were exposed to acetaminophen for 90 min (A) and then incubated
with the thiol reductant dithiothreitol (DTT) for a further 90 min (B). Despite morphological damage after 90 min, as evidenced by substantial plasma membrane
blebbing, hepatocytes could be restored to normal morphology (and function) over the subsequent incubation with DTT, demonstrating that the effectso b s e r v e d
at 90 min were fully reversible. If cells were incubated in buffer alone for the second 90 min period there was a marked loss of viability (Tee et al., 1986).
proliferation to regenerate the tissue mass that is lost. This pro-
cess is under tight control, so that apoptosis limits the extent of
tissue growth to the extent necessary to restore the functional
mass. This is a compensatory response, which occurs when the
functional reserve of the tissue is compromised by the degree
of damage. However, organs such as the liver and kidney have
sufﬁcient functional capacity to cope with a small amount of
damage without mounting a restorative response. This results in
a de facto threshold for proliferation. Proliferation, as measured
by the bromodeoxyuridine (BrdU) labelling index, is dependent
on both the duration and magnitude of exposure to chloroform.
For example, in an inhalation study in F344 rats, it was neces-
sary to expose the animals for more than 4 days to a dose of
at least 30 ppm before any increase in proliferation could be
detected in the kidney (Templin et al., 1996b). At 4 days, doses
of up to 300 ppm (highest tested) had no effect on proliferation
and similarly, with a dose of 10 ppm or less even after 13 weeks
of exposure, there was no change in proliferation. The increase
in proliferation was reversible, so that 6 weeks after exposure
to 300 ppm for 13 weeks, the proliferation rate had returned to
baseline values (Templin et al., 1996b). In the liver, no change
in proliferation was observed at doses less than 300 ppm. Qual-
itatively similar results have been reported in B6C3F1 mice,
exposed by the oral route (Larson et al., 1994). In both liver and
kidney, no proliferation was observed below a certain dose of
chloroform,andthedurationofexposureincreasedtheresponse
to a given dose.
As it is proliferation that leads to the selection or production
of pre-cancerous cells, a necessary step in the progression to
cancer, the absence of a proliferative response will result in a
clear threshold for the carcinogenic response.
Inadditiontotheextentofdamage,thepersistenceofdamage
is an important determinant of the carcinogenic response. This
needs to be sustained; otherwise there is insufﬁcient time for
selection/generation of altered cells.
The processes involved in tissue repair in humans are very
similar to those in experimental animals. Hence, while there
may be some differences in absolute sensitivity, there will still
be a threshold in the response.
DISCUSSION
Absorption and Distribution of Chloroform to Target Tissue
Target tissue dose levels of chloroform can be affected by
a variety of host factors, not all of which have been eluci-
dated. These mechanisms may include adaptive or protective
responses, which increase elimination. At high dose, the elimi-
nationofchloroformbecomessaturated.Whilethesefactorswill
contribute to inter-species and interindividual differences in re-
sponse, they do not represent an absolute barrier to the toxicity
or carcinogenicity of chloroform. On the other hand, the sys-
temic dose of chloroform, which depends upon the magnitude
of the external dose and its rate of delivery to the systemic cir-
culation, provides a clear biological threshold for the responses
of concern. Hence, when administered by certain routes and/or
below a certain dose, chloroform is not toxic.
Generation of Cytotoxic Metabolite (Phosgene) by P450
(CYP2E1)
The key event of generation of the cytotoxic metabolite
(phosgene) is rate limiting, in that the location of the thresh-
old for the response of concern, the shape of the overall dose-
response curve, and the magnitude of the ultimate response
will depend upon the levels of the causative agent that are pro-
duced, which in turn will depend upon the levels of expression
of CYP2E1. If no phosgene is produced, there will be no or-
gan toxicity and no tumorigenic response. Evidence for this is
available from a number of studies, including those in CYP2E1
homozygous knockout mice. Many factors, both genetic and
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activity of CYP2E1. These may affect the response qualita-
tively, as above, or quantitatively, in that susceptibility is altered
but not eliminated, depending on the magnitude of the change
in CYP2E1-dependent activity. While the response may also be
modiﬁedbyGSHconcentrationintargettissues,onlywhenlev-
elsaresubstantiallyimpairedisthislikelytoaffectsusceptibility
to chloroform.
Sustained Cytotoxicity
Above a certain level of phosgene, damage to cells will re-
sult in cytotoxicity, i.e. cell death. However, repair and adaptive
responses enable cells to sustain and recover from a certain
degree of damage while maintaining their viability. These pro-
cesses are not well deﬁned for chloroform, but by analogy to
similar agents, clearly play an important role in determining
the biological threshold and interindividual variability in sus-
ceptibility. While host factors can undoubtedly inﬂuence these
processes, speciﬁc information is not available. This is an as-
pect of chloroform toxicity that would be amenable to further
research to ﬁll the data gap.
Regeneration and Proliferation
Cytotoxicitymustbeofacertainmagnitudeandbesustained
for a certain period of time before proliferation is stimulated.
At lower doses or with shorter periods of exposure, adaptive
and/or repair processes enable recovery of the organ without
any increase in cell proliferation. This represents a biological
threshold. The degree to which host factors inﬂuence the prolif-
erative response following chloroform-induced cytotoxicity is
notclear,andisanareathatwouldbeneﬁtfromfurtherresearch.
Mode of Action
The earlier key events in the mode of action for the toxicity
and carcinogenicity of chloroform, those relating tometabolism
and disposition, have been studied in more detail than the later
key events, particularly for the inﬂuence of host factors. In ad-
dition, while no mode of action is strictly sequential, it is clear
that a progression from one key event to another is necessary to
provoke a carcinogenic response from chloroform. The conse-
quence is that it is not possible to determine the importance of
the more distal key events from interference with proximal key
events. For example, in CYP2E1 knockout mice, while the ab-
senceofatoxicologicalresponseisduetotheinabilitytoconvert
chloroformtophosgene,itisnotclearhowmuchofthisisdueto
thefactthatthereisnocytotoxiceffectintheseanimals.Suchan
analysis requires that each step can be studied independently of
theearliersteps.Forexample, toavoidconsiderationofchanges
in CYP2E1 expression, could the effects of phosgene be studied
directly (in this instance the experiment may be impractical)?
Similarly, to determine the importance of proliferation, it would
be necessary to induce cytotoxicity by some means that was in-
dependent of the precursor effects of chloroform. Hence, while
itisapparentthattheexpressionofCYP2E1isakeydeterminant
of the response, it is not possible to determine the relative im-
portance of host factors on the other key events in this instance.
Despite some gaps in knowledge, particularly relating to the
inﬂuence of host factors on later key events, the general conclu-
sion is that the mode of action for chloroform is such that the
dose-response would be nonlinear and a deterministic approach
to the risk assessment of this compound has been accepted by
a number of regulatory bodies, such as the US EPA (2006). In
establishing a Maximum Contaminant Level Goal for chloro-
form in drinking water, the EPA concluded that “based on an
analysis of the available scientiﬁc data on chloroform, EPA be-
lieves that the chloroform dose response is nonlinear and that
chloroform is likely to be carcinogenic only under high expo-
sure conditions” and as a consequence “chloroform is likely to
be carcinogenic to humans only under high exposure conditions
that lead to cytotoxicity and regenerative hyperplasia.”
It is clear that a key events analytic framework for a mode
of action, such as the one outlined here, is of appreciable value
in developing a science-based argument for moving from the
default of no-threshold, low-dose extrapolation to an approach
based on the concept of a biological threshold with a nonlinear
dose-response relationship. Despite this, however, there is con-
cern that because of inter-individual variability in sensitivity, it
is not possible to identify a population threshold, and hence a
precautionary approach is necessary. The key events analytic
framework provides a rational basis for addressing this con-
cern. By determining the mechanistic basis for the key events
and characterizing the degree of human variability, and the rate
limiting steps, in the underlying processes (for example see
Heinloth et al., 2004), it should be possible to establish the exis-
tenceofpopulationthresholdswiththesameconﬁdencethatitis
now possible to establish the existence of biological thresholds.
CASE STUDY: DNA-REACTIVE CARCINOGENS
As discussed above, historically, health outcomes can differ
substantially with regard to assumptions about dose-response at
low doses. For the present discussion on approaches for estab-
lishing criteria for threshold responses for adverse outcomes of
chemicalexposures,itisconvenienttoconsiderchemicalsintwo
separate health outcome related categories—carcinogens and
noncarcinogens. In general terms, carcinogens produce linear
or linear-quadratic tumor responses and noncarcinogens have
threshold dose-responses for disease outcomes. However, this
pragmatic description is being challenged, certainly at the pop-
ulation level (NAS, 2008). Further, as discussed above, carcino-
gens are considered in two clearly distinguished groups based
upon their MOA—DNA-reactive (mutagenic) and non-DNA-
reactive(e.g.receptor-mediated,mitogenic,cytotoxic,oxidative
stress). As described above, this results in a clear distinction
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(U.S.EPA,2005)betweenthesetwobroadgroups—amutagenic
MOA results in a default linear extrapolation from the POD for
human or rodent tumors, or other toxicological endpoints; a
non-mutagenic MOA can lead to a nonlinear or threshold dose-
responsebasedupontheavailablesupportinginformation.Thus,
for the consideration of potential mechanisms for the develop-
ment of threshold responses for chemical exposures, the ILSI
RF working group developed a case study for DNA-reactive
chemicals as a class rather than using a single chemical for a
case study.
DNA-Reactive Carcinogens and Risk Assessment
Asnotedabove,forcancerriskassessments,ithasbeencom-
mon practice to presume that in the absence of data to the con-
trary, the default tumor dose-response curve for DNA-reactive
(mutagenic) chemicals is linear at low doses (U.S. EPA, 2005).
This position is predicated on the assumption that even “one
molecule” of a chemical has a ﬁnite probability of inducing
cellular transformation and ultimately a tumor. The encourage-
ment through the recently published U.S. EPA Guidelines for
Carcinogen Risk Assessment (U.S. EPA, 2005) to incorporate
mechanistic data into the cancer risk assessment process has
allowed for reconsideration of the default linear approach. Such
reconsideration can be placed in the context of the new types
of data that can be generated using the most recent molecular
biology methods. These can inform the mode of action and help
characterize the mechanisms of tumor formation (Edwards and
Preston, 2008).
Relationship of Initial DNA Damage to Mutagenic Events
DNA-reactivechemicals(ortheirmetabolites)produceDNA
damage (e.g., adducts, crosslinks) through the covalent binding
of the reactive form of the chemical to DNA. In a general sense,
DNA damage can be converted into a mutation by errors of
replication on a damaged template or by errors of DNA repair.
However, for the great majority of chemical carcinogens, these
mutations are produced almost exclusively through errors of
DNA replication (Preston, 1991). It should be noted that while
the dose-response curve for DNA adducts is generally linear, it
does not follow that dose-response curves for gene mutations
or chromosomal mutations are linear over a broad dose range
(Swenberg et al., 2008). Thus, the dose-response curve for mu-
tations can be considered to be a probability curve denoting the
probability as a function of dose (or DNA adduct level) that
DNA damage can be converted into a mutation. The probability
ofconvertinganadductintoamutationisnotequallylikelyover
a range of doses including low (environmental) ones (Ottender
and Lutz, 1999).
The various steps from the initial formation of a critical
mutation to a tumor are based on the generally accepted
models of multistage carcinogenesis [for example, Fearon and
Vogelstein (1990); Hanahan and Weinberg (2000); Mantovani,
(2009)]. From this multistage characterization, the overall
shape of the tumor dose-response can be considered to be an
integration of the individual probability curves for the key
events essential for tumor development following exposure to
a DNA-reactive carcinogen.
Key Events Dose-Response Analysis
The particular pathway whereby a chemical can produce an
adverse outcome is described by its mode of action (MOA).
These pathways include DNA-reactivity, receptor-mediated re-
sponses, cytotoxicity with regenerative cell proliferation, and
mitogenicity. In turn, a MOA is deﬁned as a sequence of key
events and processes, starting with interaction of an agent with
a cell, proceeding through functional and anatomical changes,
and resulting in cancer formation (or formation of a non-cancer
health outcome). A key event is an empirically observable pre-
cursor step that is itself a necessary element of the MOA or is a
biologically based marker for such an element. In the context of
the dose-response characteristics for the adverse outcome, it is
necessary to consider the plausible dose-response characteris-
tics for each of the key events for a particular adverse outcome
andfurthertoestablishifoneormoreoftheseisadeterminantof
the dose-response for the adverse outcome, either quantitatively
or qualitatively. In this way it should be possible to establish if
a real (or practical) threshold could be predicted for an adverse
outcome. For the present discussion, the adverse outcome is
cancer. The example that will be discussed here is that of DNA-
reactive chemicals. The key events that lead along the path from
uptake and distribution of the chemical though initial exposure
of the target cells for cancer formation to ﬁnal outcome of a
metastatic tumor have been presented by Preston and Williams
(2005) and are:
1. Uptake and distribution of chemical within the body.
2. Exposure of target cells (e.g., stem cells) to ultimate
DNA-reactive and mutagenic species, with or without
metabolism.
3. ReactionwithDNAintargetcellstoproduceDNAdamage.
4. Misreplication on damaged DNA template or misrepair of
DNA damage.
5. Mutations in critical genes in replicating target cells.
6. Critical gene mutations result in initiation of new DNA/cell
replication.
7. New cell replication leads to clonal expansion of mutant
cells.
8. DNA replication can lead to further mutations in critical
genes.
9. Imbalanced and uncontrolled clonal growth of mutant cells
may lead to preneoplastic lesions.
10. Progression of preneoplastic cells results in emergence of
overtneoplasms,solidtumors(whichrequireneoangiogen-
esis), or leukemia.
11. Additional mutations in critical genes as a result of uncon-
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Thereisrelatively littleinformation ontheshape ofthedose-
response for any of these key events (including mutations and
chromosomealterations)becausesomanystudiesareconducted
for hazard identiﬁcation using a limited number of doses and
dose range or are for mechanistic studies where most frequently
rather high exposures are used. In a few cases a broad range
of concentrations has been used for in vitro mutation assays
and there is some evidence for nonlinear responses, perhaps
including threshold responses when viewed within the context
of the background mutation frequency and the associated er-
rors (Doak et al., 2007; Swenberg et al., 2008). There is a
need to distinguish between gene mutations (involving 1 or
2 bases) and chromosomal mutations involving large segments
of DNA (e.g. deletions, translocations, inversions). The reason
is that on the basis of the “hit” theory, as usually described
for ionizing radiation effects, a gene mutation would be pre-
dictedtorequireonehitwhereaschromosomealterationswould
require two hits. The consequence is that the dose-response
curve for gene mutations (above any threshold that might ex-
ist) would be linear with the dose, whereas that for chromo-
some mutations would be proportional to the (dose).2 For the
majority of chemicals the overall tumorigenic response would
be a combination of the two endpoints resulting in a “linear-
quadratic” dose-response curve. The ratio of the linear and
quadraticcomponentswouldbechemical-speciﬁc,i.e.morelin-
ear or more quadratic. Whether a threshold would be predicted
at low exposures is open to discussion; at least, an effective
threshold, in the context of increase over background, can be
predicted.
Inthevirtualabsenceofexperimentaldataontheshapeofthe
dose-responsecurveforthesekeyeventsatlow(environmental)
exposure levels, it is appropriate to consider each key event in
the context of what would be necessary for a threshold response
to be predicted initially for an experimental animal MOA and
then,byusingahumanrelevanceframework(Meeketal.,2003),
for exposed humans.
Key Event 1—Exposure of Target Cells to Ultimate DNA
Reactive and Mutagenic Species—With or Without
Metabolism
This Key Event is likely to be rate-limiting because without
exposure to the target, other key events cannot occur. Such a
failure of a chemical to reach the target cells could be expo-
sure dependent. For a threshold response (over any particular
concentration range) the inability of the parent chemical or the
active metabolite to reach the target cells will result in the ab-
sence of an effective dose. It is important to use as much data
for humans to establish whether or not a rodent response, as
regards the target tissue dose, is plausible in humans. Simi-
larly, the lack of the necessary metabolizing enzymes or en-
zyme activity for activating a speciﬁc chemical in a speciﬁc
target cell will lead to the absence of an effective dose. Again,
assessing plausibility in humans from available rodent data is
necessary.
Key Event 2—Reaction with DNA in Target Cells to Produce
DNA Damage
This Key Event is, of course, in part dependent on Key
Event 1 for plausibility in humans. Of particular importance
(for chronic exposures) is the steady-state level of DNA dam-
age. There is a continual production and repair of DNA damage
and at very low levels of exposure (and DNA damage) it is quite
feasible that all DNA damage is repaired essentially immedi-
ately. The concern, in terms of eventual cancer outcome, is not
the induction of DNA damage, but rather the accuracy and ki-
netics of its repair or the levels of damage that are present in any
segment of DNA at the time of its replication. For a threshold
response, DNA damage would need to be at a “zero” or “very,
very low” steady state, or it would need to be repaired without
error or not be present at the time of replication (Chan et al.,
2006).
Key Event 3—Misreplication on a Damaged DNA Template or
Misrepair of DNA Damage
This Key Event follows from the induction of DNA damage,
and represents how the damage itself can be converted into a
biological event, namely a mutation (point or chromosomal).
DNA replication and repair processes have a background error
rate that is low (Budzowska and Kanaar, 2009). The addition
of an additional low level of induced damage from a chemi-
cal exposure is unlikely to increase this rate. However, for a
threshold response for this key event it is necessary that errors
in replication be effectively “zero” above background. There is
insufﬁcientinformationavailabletoreachsuchaconclusion,al-
thoughtherearemutationdatathatsuggestthisisthecase(Doak
et al., 2007). Another consideration is that for DNA damage to
be converted into a mutation, cell replication is required. DNA
repair errors are considered to be even lower than replication
errors (Preston, 1991). Thus, if there is no replication in the tar-
get cells there will be no mutations produced. If there is a very
lowreplicationrate,thentheracebetweenrepairandreplication
will be in favor of repair, thereby reducing the probability for
producingamutationandperhapscreatingapracticalthreshold.
Key Event 4—Mutations in Critical Genes in Replicating
Target Cells
For Key Event 3 described above, the mechanism by which
mutationscanbeproducedisdiscussed.TheneedforKeyEvent
4 is that such mutations be in critical genes. A prediction of this
likelihood is, in part, dependent on the number of “cancer”
genes present in the total genome. The most recent estimate is
that there are about 120 “driver” genes for oncogenesis out of
a total human genome of some 23,000 genes (Greenman et al.,
2007). Thus, the probability of inducing a critical mutation is
very low at extremely low levels of replicating DNA damage.
A calculation would almost certainly demonstrate a practical
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Key Events 5–11
The other Key Events (#s 5–11) naturally follow from the
ﬁrst 4. Since each Key Event is dependent on the qualitative and
quantitative features of the dose-response for Key Events 1-4,
any prediction of athreshold (real or practical) fromKey Events
1-4 will inﬂuence discussion of subsequent Key Events in the
context of a threshold. To obtain multiple mutations in a single
cell which is necessary for the multistage tumor model that is
currentlytheacceptedone[includingthatdevelopedinHanahan
andWeinberg’sHallmarksofCancer(2000)]willfurtherreduce
the probability of producing Key Event 7. The probability is
very low for producing critical mutations in target cells from
low level exposures in repair proﬁcient, replication efﬁcient
cells; this probability is reduced dramatically by requiring that
these multiple mutations be in a single cell. A linear low dose-
response for a single mutation cannot be used to predict the
response for multiple mutations in a single cell over the same
dose range.
Exposure-To-Outcome/Effect Continuum
It is of particular importance to note that the set of key events
developed for tumors (discussed above) are a dependent set and
not an independent one. Each step along the pathway from a
normal cell to a transformed cell phenotype and ultimately to
a tumor is dependent on the previous step. As described, the
quantitative nature of each step (or key event) can be consid-
ered as the probability that a particular key event is converted
into the subsequent key event. Certainly this continuum and
the probabilistic nature of key event production would allow
for the presence of threshold responses even for DNA-reactive
chemicals.
Characteristics of Stressor/Host/Exposure Matrix
For DNA-reactive chemicals, the assessment of risk is
broadly conducted for the “average” individual (in a popula-
tion) in the absence of other confounding exposures. Clearly,
risk will be inﬂuenced by other exposures, either increasing or
decreasing ultimate tumor response to the chemical whose risk
is being assessed. While potential sensitivity (susceptibility)
factors (especially early life stage exposures) are considered,
they are generally covered by default application. It could be
argued that susceptible individuals will always fall outside any
threshold response because threshold responses are always con-
sidered in terms of background levels and the background level
for susceptible individuals is (by deﬁnition) above the normal
background frequency of an adverse outcome, such as cancer.
In a general sense, susceptibility factors per se can have an
inﬂuence at any or all key events, depending on the nature of
the susceptibility, for example, for DNA repair effectiveness,
the extent of metabolism, the speciﬁc metabolic pathways, and
cytotoxicity.
Our understanding of how to incorporate chemical mixtures
that include DNA-reactive carcinogens and susceptibility into
the cancer risk assessment process is still very much an imper-
fect science and is an area that is ripe for research efforts.
Principles and Implications for Thresholds
ForDNA-reactivechemicals,anyassessmentoflow-dosere-
sponse has to be put in the context of the background frequency
of DNA damage and of genetic alterations. The low-dose re-
sponse also has to include considerations of the efﬁciency of
DNA repair—is its error rate dependent on dose; i.e., the level
of DNA damage? The underlying principle is, given the rela-
tively high levels of background DNA damage [e.g. the steady-
state level of 500 base alterations per cell (Barnes and Lindahl,
2004)], what is the likelihood that a small amount of additional
(induced) DNA damage will elicit an adverse response, namely
genetic alterations and tumors? A second principle is how de-
pendent is an increase in the level of genetic alterations at low
doses on an increased (induced) level of cell proliferation? A
thirdprincipleis,giventhattumorformationdependsonthepro-
duction of genomic instability, how likely is this to be induced
by chemical exposures at low doses?
All of these principles impact the likelihood of there being
threshold responses (or nonlinear responses) for genetic alter-
ations and/or tumors at low levels of exposure to DNA-reactive
chemicals.
Identiﬁcation of the Types of Data Required to Characterize
Low Dose Dose-Response Relationships for DNA-Reactive
Chemicals
The types of study that can have an impact on our under-
standing of the possibility of threshold responses for tumors
induced by DNA-reactive chemicals will be those that address
the issue of the low-dose response of the key events and factors
that either increase or decrease these. The following is a list of
possible data needs:
• Background levels of DNA damage.
• Background levels of genetic alterations.
• Dose-response curves for DNA adducts and genetic alter-
ations over a low dose range.
• DNA repair characteristics at low doses.
• Rate of induced cell proliferation at low doses.
• Identiﬁcation of reliable biomarkers of response based on key
events for characterizing low dose effects.
Application of New Technologies for Understanding Low
Dose Dose-Responses and Key Current Gaps in Knowledge
The likely progress leading to a better understanding of the
dose-response for adverse health outcomes following exposure
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the pathway from a normal to a pathologic state. The identi-
ﬁcation of informative markers of key events can be greatly
enhanced by the use of whole genome techniques such as gene
expressionassessments[usingmicroarraysorpreferablymRNA
counting techniques such as SAGE or ultra-high throughput se-
quencing(Mardis,2008)],orproteomicassessment[usingmass
spectrometry based techniques (Latterich et al., 2008)]. These
approaches have the great advantage of being able to use data
from the whole genome that will include gene-gene, protein-
protein, and cell-cell interactions, for example. The ability to
conduct these types of studies on very small tissue samples will
enhance the ability to focus on altered cells without the con-
founding from normal cells. It is essential that computational
approaches be used in parallel with data gathering exercises in
order to be able to interpret the molecular data in a whole cell
(or tissue) context (for example, Wu and Dewey, 2006). In this
regard, molecular modeling techniques are an essential compo-
nent of assessing low-dose responses where it is very difﬁcult to
obtain all the necessary informative experimental data. The ma-
jority of mutations associated with diseases are at nonselectable
loci that makes their quantitation difﬁcult in a technical sense.
Thereareanumberofmoleculartechniques,especiallythose
based on PCR technology, that are reaching sensitivity levels in
the range required (1 in 107 cells) for the study of induced mu-
tations (Morlan et al., 2009). These will certainly be perfected
in the near future.
CASE STUDY: ENDOCRINE-ACTIVE AGENTS
Endocrine disruption is a term that was coined to describe
the adverse effects produced by toxicants that interfere with
normal endocrine function. Endocrine disrupters can act by in-
terfering with the synthesis or elimination of hormones, but
probably the most important mechanisms are those involving
interaction (either agonism or antagonism) with steroid hor-
mone receptors. Steroid hormone receptors and other receptors
within the nuclear hormone receptor family have small endoge-
nous ligands that are stable and capable of diffusing across cell
membranes to interact with their receptor, which is located in
the cytoplasm or nucleus. Unlike membrane-bound receptors,
which tend to have a rapid signal transduction process (e.g.,
the opening of a membrane channel, the phosphorylation of a
protein), the signal transduction process for ligands of nuclear
hormone receptors is slower and involves a speciﬁc pattern of
gene expression. The receptor-ligand complex binds to speciﬁc
response elements on the genome, which brings about selective
up- and down-regulation of gene expression. The end result of
this gene expression, and subsequent translation into proteins
is to change the function and/or state of differentiation of the
cell over a time course ranging from hours to days. Exoge-
nous compounds that mimic the endogenous hormone can elicit
inappropriate responses either by acting as agonists or antag-
onists. Although nuclear hormone receptors have high afﬁnity
and speciﬁcity for their endogenous ligand, some, such as the
estrogenreceptor,arecapableofaccommodating,albeitweakly,
many other chemical structures in their binding sites.
There are a large number of steroid hormone receptors, with
effects on virtually every organ system, although most oper-
ational deﬁnitions of endocrine disrupters concentrate on sex
steroids and thyroid hormones. Endocrine disrupters have the
potential to cause reproductive toxicity, developmental toxicity,
orcertaintypesofcancerinhormonallyresponsiveorgans,such
as the uterus, the mammary gland, or the testis. Developmental
effectsofsomeofthesetoxicants,particularlythosethatinteract
withtheestrogenreceptor,maybelatent,withfewobviousstruc-
tural effects in the fetus or neonate, but persistent effects on re-
productive function when the organism reaches sexual maturity.
For the purposes of this review, we will use estrogens and
interaction with the estrogen receptor as an example system by
whichtoassessthenotionofthresholdsforendocrinedisrupters.
Estrogens inﬂuence a number of systems, but are particularly
important in the development of the reproductive system and
in the regulation of normal female reproductive function. The
normal function of hormones is to bring about changes in the
state of differentiation or function of cells for a period of hours
to days. An excellent example is the rodent estrus cycle (or its
corollary, the human menstrual cycle) in which the synthesis
and release of estrogens, followed by progestagens, results in a
predictable cycle of changes in the ovary, the uterus, the vagina,
the pituitary, and CNS, returning to the initial state at the end of
eachcycle.Therodentuterotrophicresponsedrivenbyestrogens
is a consequence of a characteristic proﬁle of gene expression
changes that occurs in a temporal pattern progressing through
transcription factors that initiate changes in the state of cellular
differentiation, induction of cell cycle machinery that drives
proliferation, and eventually the induction of inﬂammatory and
pro-apoptotic factors that drive the return of the organ to its
uninduced state (Moggs et al., 2004, Fertuck et al., 2003, Naciff
et al., 2007). Although these responses are mediated at the level
of the receptor and gene, they require the coordinated action
of a large number of genes within each cell, and the change in
function of large numbers of cells in different tissues in order
to produce a physiological response. It seems unlikely that the
estrus cycle of rodents could be perturbed in a nonthresholded
way. High concentrations of endogenous estrogen are needed to
elicit the ovarian, uterine, and vaginal changes that are integral
to the estrus cycle. The response is generally maximal; i.e.,
addingmoreestrogendoesnotincreasethemassoftheuterusor
make the vaginal epithelium more corniﬁed. Antagonists of the
estrogen receptor have the potential to decrease the magnitude
of the response, but because of the high level of endogenous
estrogen that is present to drive the onset of estrus, it is not
possiblethatthedisplacementofasingleagonistmoleculefrom
a single receptor (which is the deﬁnition of a non-threshold
response) would have any effect, even at the level of a single
cell, on the response to estrogens.
While the changes elicited by estrogens and progestagens
may be dramatic (e.g., a several-fold increase in uterine weight,
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represent normal physiological states. This range of normality
needs to be taken into account when assessing whether hor-
monal effects are adverse, either by elicitation of a sub- (or
supra-) normal response, or persistence in a physiological state
that is intended to be transitory. The relevance of this distinction
for thresholds is that the threshold must lie above the physiolog-
ical range of function for the hormone. A similar concept was
developedfortoxiceffectsforaneurologicalfunctionwhichcan
perform normally within a range of values for neurochemical
concentrations, behaviors, etc. (Gaylor and Slikker, 1994).
There are a couple of points to consider in determining
whether thresholds exist for hormones. The ﬁrst is to determine
whethertherearecircumstancesinhumanphysiologywherethe
action of a single molecule of a hormone, or the inhibition of
the action of a single hormone molecule, could change a biolog-
ical response. The second, arguably more important, question
is whether addition to the existing background levels of a hor-
mone would be sufﬁcient to drive a biological response. We can
consider examples of both using the key events dose-response
framework.
For the ﬁrst case, let us consider the role of estrogens and
luteinizing hormone in stimulating ovulation. During the late
diestrus and proestrus phases of the estrus cycle, the ovary re-
leases a large quantity of estradiol. Although estrogens gener-
ally inhibit GnRH secretion, the high levels of estrogens present
during proestrus have the opposite effect, stimulating GnRH se-
cretion by the hypothalamus. This in turn stimulates a spike of
LH and FSH secretion by the pituitary. The LH surge induces a
numberofbiochemicalandstructuralchangesinmatureovarian
follicles that result in their rupture and release of ova, as well as
the differentiation of granulosa cells into luteal cells. (In reality,
there are more steps and more hormones involved in ovulation,
but for the sake of illustration we can keep the example simple.)
Wecanconsidertheretobeseveralkeyeventsinthisexample—
thesynthesisofasufﬁcientlyhighlevelofestradiolbytheovary
to produce a stimulatory effect on the hypothalamus; the release
of GnRH from the hypothalamus and its action on the anterior
pituitary; and the release of LH from the pituitary in sufﬁcient
quantity, at the right time, to stimulate ovulation. Each of these
steps can be analyzed to determine whether it is likely to be
thresholded.
The ﬁrst step, the synthesis of a sufﬁcient quantity of estra-
diol by the ovary during late diestrus/ early proestrus, could
ostensibly be affected by treatment with a steroid synthesis in-
hibitor. Steroid synthesis inhibitors can affect fertility; however,
it is unlikely that this effect would be nonthresholded. The syn-
thesis of estradiol in the ovary takes place in a large number of
cells, such that a reduction in the capability of one would have
no measurable effect. There is also likely to be plasticity in the
quantity of steroidogenic enzymes in a cell, in that inhibition
of enzyme activity would also lead to rapid induction of en-
zyme activity. There is some empirical evidence that the effect
of steroid synthesis inhibitors on ovarian estrogen synthesis is
nonlinear(i.e.,thresholded).Powlinetal.(1998)reportednoef-
fect of up to 1 µM aminoglutethamide, an aromatase inhibitor,
(with signiﬁcant decreases starting at 10 µM) on estradiol syn-
thesis by the explanted rat ovary. Shin et al. (2006) reported
prolongation of the estrus cycle in a 28-day study, with asso-
ciated increases in estradiol, LH and FSH (which were likely
compensatory to steroid inhibition), but with clear nonlinearity
in the dose-response relationship.
Secretion of GnRH and the elicitation of LH release is also
a multi-cellular process and therefore unlikely to be affected
by the activity of a single molecule of toxicant in a single cell.
However, the LH surge needs to reach a certain magnitude in
ordertoeffectivelystimulateovulation,possiblymakingitmore
vulnerable to small changes in GnRH. Curtailing the LH surge
prevents ovulation; delay of the surge may also hinder ovula-
tion, and results in ovulation being out of synchrony with the
estrus cycle, either of which can impair fertility and fecundity.
However,studieswithavarietyofdifferentagentsthatcanblunt
the LH surge at sufﬁciently high dose levels, suggest a nonlin-
earity in the dose-response curve (e.g., Laws et al., 2000). From
a theoretical standpoint it makes sense that this response would
be thresholded, as it is controlled by a group of cells, so that
an effect of a single molecule or dysfunction of a single cell is
unlikely to have a noticeable impact on the end result. However,
the fact that the increase in LH does not have to be fully inhib-
itedtohaveanadverseeffectonovulationdoesindicatethatitis
likely to be a sensitive step in the control of ovulation, although
not necessarily a nonthresholded step.
Probably the more important theoretical consideration rele-
vanttothresholdsisthatofadditivitytoanexistingbackground.
Generally, the endogenous ligand for a hormone receptor is
present at some concentration. Is it possible for the endogenous
hormone to be present at sufﬁciently high levels during certain
physiological states that the addition of even a single molecule
of an exogenous ligand is sufﬁcient to drive the response from
one that is physiological to one that is adverse?
The aspects of development that are controlled by estrogens
maybethemostsensitivetoadverseeffectsofestrogenagonists.
Is it possible that these effects are nonthresholded? There are
some specialized cases in which minute changes in the estrogen
level can lead to a change in the developmental outcome. An
exampleofthisisthetemperature-sensitivesexdeterminationin
red-eared slider turtles, in which the temperature determines the
aromatase activity, which in turn mediates estrogen synthesis,
and the level of estrogen in the egg determines sex, a phe-
nomenon that appears to be best explained as nonthresholded
(Sheehan, 2006). Exogenous estrogens or aromatase inhibitors
cansubstitutefortemperatureinmodulatingthesexratio.Inthis
example, the level of estrogen synthesized in the eggs is already
sufﬁcient to drive sexual differentiation at the temperatures typ-
ically encountered by this species; in other words, the level of
endogenous estrogen under normal conditions for this species
is already midway up the dose-response curve, and any change
in estrogen levels would lead to changes in the developmental
outcome.
Sex determination is not quite as plastic in mammals. How-
ever, although the chromosomal aspect of sex determination704 A. R. BOOBIS ET AL.
is hardwired, the androgens can signiﬁcantly masculinize the
female fetus and antiandrogens can drive the morphological de-
velopmentofthemalereproductivesysteminafemaledirection.
Forexample,vinclozolin,whichhasantiandrogenicactivity,has
been shown to decrease the anogenital distance in male rats in
a linear fashion down to fairly low dosages (Gray et al., 1999).
It is not possible to determine whether this effect is thresholded
by morphology alone, as the variability in the measurement
would overwhelm the ability to detect very small changes in a
reasonable number of animals.
This problem of methodological limitations has made it dif-
ﬁcult to reach conclusions about additivity to the background
because it has not been possible to design experiments that have
sufﬁcient sensitivity to determine whether very small doses of
a compound have any effect. New technology in the form of
genome-wide gene expression analysis has the potential to rem-
edy this problem. Gene expression analysis has the sensitivity
to determine whether these purported effects are real. Avail-
able methods like microarray techniques, real-time RT-PCR,
and bead-based oligonucleotide methods have sensitivities in
the subattomole range (Naciff et al., 2005a). When combined
with the power to query the entire genome (by microarray)
to ensure that unexpected changes in gene expression are not
missed, this is a powerful tool to address the potential low-dose
effects of agents like estrogens for which the signal transduc-
tion process is dependent on gene expression. Gene expression
has been analyzed in fetal rat testis exposed transplacentally
to three different compounds with estrogenic activity—ethinyl
estradiol, genistein, and bisphenol A. Doses for each compound
spanned ﬁve or six orders of magnitude, starting from a dosage
known to have pharmacological activity, down to extremely low
dose levels. All three compounds have effects on gene expres-
sion at the higher dose levels, and there are still some effects
on gene expression at doses lower than those that had mor-
phological effects; however, at the lowest dose levels of these
compounds there were no changes from control in gene ex-
pression (Naciff et al., 2005b). This result strongly suggests a
threshold for activity of estrogens on gene expression during
development. More work needs to be done to provide additional
data sets that are comparably comprehensive, but gene expres-
sion analysis appears to be a promising experimental approach.
While the methodology is still not sensitive enough to deﬁni-
tively demonstrate a threshold, it may be sufﬁciently sensitive
toeliminatethedifferencebetweenrealthresholdsandtheprag-
maticthresholdsthatrepresentambientenvironmentalexposure
levels. That, plus the advantage that genome-wide microarrays
cover the entire possible range of gene expression, makes mi-
croarraytechnologyanattractiveoptionforplumbingthedepths
of the dose-response curve.
CONCLUSIONS
This paper presents different approaches to evaluate the na-
ture of the low end of the dose-response curve and the possible
existence of thresholds for toxic agents, using a key events
dose-response framework as a consistent way for presenting
and analyzing the critical steps in a toxic process. The general
conclusion is that there are rate-limiting key events that, if not
met, can lead to a threshold for the dose-response, irrespective
of the MOA involved.
Tofurtheraddressthisissue,advantagecanbetakenofscien-
tiﬁc advances that have made it possible to address the question
of thresholds in a variety of ways. For example, it is possible
to conduct research that provides a deep and thorough mech-
anistic understanding of the critical events in the toxicity of a
particular agent thereby leading to qualitative and quantitative
considerations of key events. As examples of this approach, in
this paper we use the extensive literature on chloroform to an-
alyze the biological basis for the nonlinearity in dose-response
for chloroform, a hepatotoxicant and nongenotoxic carcinogen
in rodents. It is also feasible to use a fundamental understand-
ing of the biology underlying a disease process as the basis for
constructing a key events framework for that process. In this
paper, we take advantage of a more profound understanding of
the molecular events that drive carcinogenesis to describe a key
events framework for genotoxic carcinogens. A third approach
is to use more sensitive technology to elucidate the low end of
the dose-response curve. We illustrate this for endocrine-active
agents,whicharelikelytobeinherentlythresholded(exceptina
few unusual cases) but for which the main concern is additivity
to the endogenous background activity of hormones. Microar-
ray technology for the global analysis of gene expression may
be a sensitive enough tool to address the low end of the dose-
response curve down to and below ambient exposure levels,
thereby providing a basis for establishing pragmatic thresholds.
These case studies contribute to a more robust basis for the
assumption that many, if not all, toxicological effects exhibit
biological thresholds and provide guidance on research needs
to further address this question.
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